Acurex Biosciences to Present Early Clinical Results Supporting its Novel Parkinson’s Disease Biomarkers at a Michael J. Fox Foundation Biomarkers Workshop
SAN CARLOS, Calif.--(BUSINESS WIRE)--Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present early results on its IRB-approved clinical trial for Parkinson’s disease (PD) patients. This longitudinal study evaluates Acurex’s first-in-class non-invasive biomarkers that detect the underlying biology of...
